Form 4: BioXcel CSO Granted 70,000 RSUs

BioXcel Therapeutics' Chief Scientific Officer, Frank Yocca, was granted 70,000 Restricted Stock Units with a two-year vesting schedule.

Summary

• Frank Yocca, Chief Scientific Officer of BioXcel Therapeutics, Inc. (BTAI), was granted 70,000 Restricted Stock Units (RSUs) on January 1, 2026.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
• The RSUs will vest as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the 'Vesting Commencement Date').
• The remaining 75% will vest in three equal installments of 25% on the last day of each subsequent six-month period thereafter.
• The RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to continuous employment with the Issuer through the relevant vesting dates.
• Following this transaction, Frank Yocca beneficially owns 70,282 derivative securities.

Sentiment

Score: 6

Explanation: Slightly positive, as it indicates executive retention and alignment of interests, which are generally favorable for corporate stability and long-term strategy, without significant immediate negative impact.

Positives

• The RSU grant aligns the Chief Scientific Officer's long-term interests with those of shareholders, incentivizing sustained performance and company growth.
• The vesting schedule promotes executive retention by requiring continuous employment for the full two-year period to receive all shares.

Negatives

• The future issuance of 70,000 shares upon vesting will result in minor dilution for existing shareholders, although this is a standard component of executive compensation.

Risks

• The vesting of the RSUs is contingent upon Frank Yocca's continuous employment with BioXcel Therapeutics through the specified vesting dates, meaning unvested RSUs could be forfeited if employment ceases.

Future Outlook

The RSU grant indicates a commitment to retaining key executive talent and aligning their long-term incentives with the company's performance over the next two years, subject to continuous employment.

Industry Context

The grant of Restricted Stock Units to a Chief Scientific Officer is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive compensation packages designed to attract, retain, and motivate top talent while aligning their interests with long-term shareholder value.

Comparison to Industry Standards

• This RSU grant is consistent with standard executive compensation practices observed across the biotechnology and pharmaceutical sectors, where equity awards are frequently used to incentivize long-term performance and retention.
• The vesting schedule, with an initial cliff and subsequent periodic vesting over two years, is a common structure for such awards, comparable to practices at companies like Moderna, Pfizer, or Amgen for similar executive roles, though the specific number of units would vary based on company size, executive level, and compensation philosophy.

Stakeholder Impact

• Shareholders: Potential minor future dilution upon vesting, but also benefit from increased alignment of executive interests with long-term company performance.
• Employees: The grant to a key executive can signal stability and commitment to leadership, potentially boosting morale.
• Management: Frank Yocca's compensation package is enhanced, providing a strong incentive for continued dedication and performance.

Next Steps

• The RSUs will begin vesting on the six-month anniversary of November 4, 2025, with subsequent vesting installments every six months thereafter.
• Frank Yocca must maintain continuous employment with BioXcel Therapeutics to ensure the full vesting of the granted RSUs.

Key Dates

Keywords

BioXcel Therapeutics, BTAI, Restricted Stock Units, RSU grant, executive compensation, insider transaction, Form 4, Frank Yocca, Chief Scientific Officer, equity award